Effect of omega-3 fish oil on cardiovascular risk in diabetes

Diabetes Educator

Volumn 36, Issue 4, 2010, Pages 565-584

  McEwen, Brad ^a   Morel Kopp, Marie Christine ^a   Tofler, Geoffrey ^b   Ward, Christopher ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FISH OIL; LIPID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; BLOOD; DIABETIC ANGIOPATHY; DRUG EFFECT; HUMAN; HYPERTENSION; INFLAMMATION; METABOLISM; PHYSIOLOGY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

DIABETIC ANGIOPATHIES; FATTY ACIDS, OMEGA-3; FISH OILS; HUMANS; HYPERTENSION; INFLAMMATION; LIPIDS; LIPOPROTEINS, VLDL; PLATELET ACTIVATION; PLATELET AGGREGATION; TRIGLYCERIDES;

EID: 78149364623     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721710372675     Document Type: Article

References (89)

1. Prabhakaran P., Ajay VS, Prabhakaran D.,et al.Global cardiovascular disease research survey. J Am Coll Cardiol. 2007;50:2322-2328.
2. Lloyd-Jones D., Adams R., Carnethon M.,et al.Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21-181.
3. Howes JM, Keen JN, Findlay JB, Carter AM The application of proteomics technology to thrombosis research: the identification of potential therapeutic targets in cardiovascular disease. Diab Vasc Dis Res. 2008;5:205-212.
4. Saito Y., Yokoyama M., Origasa H.,et al.Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008;200:135-140.
5. Benatti P., Peluso G., Nicolai R., Calvani M. Polyunsaturated fatty acids: biochemical, nutritional and epigenetic properties. J Am Coll Nutr. 2004;23:281-302.
6. Jung UJ, Torrejon C., Tighe AP, Deckelbaum RJ n-3 fatty acids and cardiovascular disease: mechanisms underlying beneficial effects. Am J Clin Nutr. 2008;87:2003S-2009S.
7. Agren JJ, Vaisanen S., Hanninen O., Muller AD, Hornstra G. Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation. Prostaglandins Leukot Essent Fatty Acids. 1997;57:419-421.
8. Singer P., Wirth M. Can n-3 PUFA reduce cardiac arrhythmias? Results of a clinical trial. Prostaglandins Leukot Essent Fatty Acids. 2004;71:153-159.
9. Sucic M., Katica D., Kovacevic V. Effect of dietary fish supplementation on lipoprotein levels in patients with hyperlipoproteinemia. Coll Antropol. 1998;22:77-83.
10. Axelrod L., Camuso J., Williams E., Kleinman K., Briones E., Schoenfeld D. Effects of a small quantity of omega-3 fatty acids on cardiovascular risk factors in NIDDM. A randomized, prospective, double-blind, controlled study. Diabetes Care. 1994;17:37-44.
11. Engler MM, Engler MB Omega-3 fatty acids: role in cardiovascular health and disease. J Cardiovasc Nurs. 2006;21:17-24.
12. Mori TA, Beilin LJ, Burke V., Morris J., Ritchie J. Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol. 1997;17:279-286.
13. Nettleton JA, Katz R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J Am Diet Assoc. 2005;105:428-440.
14. Nordoy A., Hatcher L., Goodnight S., Fitzgerald GA, Conner WE Effects of dietary fat content, saturated fatty acids, and fish oil on eicosanoid production and hemostatic parameters in normal men. J Lab Clin Med. 1994;123:914-920.
15. Westerveld HT, de Graaf JC, van Breugel HH,et al.Effects of low-dose EPA-E on glycemic control, lipid profile, lipoprotein (a), platelet aggregation, viscosity, and platelet and vessel wall interaction in NIDDM. Diabetes Care. 1993;16:683-688.
16. Woodman RJ, Mori TA, Burke V.,et al.Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis. 2003; 166:85-93.
17. Burr ML, Fehily AM, Gilbert JF,et al.Effects of changes in fat, fish, and fiber intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;2:757-761.
18. Dyerberg J., Bang HO Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet. 1979;2:433-435.
19. Hu FB, Bronner L., Willett WC,et al.Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA. 2002;287:1815-1821.
20. Hu FB, Cho E., Rexrode KM, Albert CM, Manson JE Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation. 2003;107:1852-1857.
21. Marchioli R., Barzi F., Bomba E.,et al.Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105:1897-1903.
22. Virtanen JK, Mozaffarian D., Chiuve SE, Rimm EB Fish consumption and risk of major chronic disease in men. Am J Clin Nutr. 2008;88:1618-1625.
23. Yamagishi K., Iso H., Date C.,et al.Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. J Am Coll Cardiol. 2008;52:988-996.
24. Zhao YT, Chen Q., Sun YX,et al.Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Ann Med. 2009;41:301-310.
25. Natali A., Pucci G., Boldrini B., Schillaci G. Metabolic syndrome: at the crossroads of cardiorenal risk. J Nephrol. 2009;22:29-38.
26. Cornier MA, Dabelea D., Hernandez TL,et al.The metabolic syndrome. Endocr Rev. 2008;29:777-822.
27. Vaduganathan M., Alviar CL, Arikan ME,et al.Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J. 2008;156:1002e1-1002e7.
28. Fruchart JC, Sacks FM, Hermans MP,et al.The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008;5:319-335.
29. Bays HE, Tighe AP, Sadovsky R., Davidson MH Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6:391-409.
30. Schectman G., Kaul S., Kissebah AH Effect of fish oil concentrate on lipoprotein composition in NIDDM. Diabetes. 1988;37:1567-1573.
31. Mooradian AD Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5:150-159.
32. Colwell JA, Nesto RW The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26:2181-2188.
33. Grant PJ Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007;262:157-172.
34. Carr ME Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001;15:44-54.
35. Razmara M., Hjemdahl P., Ostenson CG, Li N. Platelet hyperprocoagulant activity in type 2 diabetes mellitus: attenuation by glycoprotein IIb/IIIa inhibition. J Thromb Haemost. 2008;6:2186-2192.
36. Sobel BE, Schneider DJ Platelet function, coagulopathy, and impaired fibrinolysis in diabetes. Cardiol Clin. 2004;22:511-526.
37. Coban E., Kucuktag S., Basyigit S. Platelet activation in subjects with impaired glucose tolerance. Platelets. 2007;18:591-594.
38. Vinik AI, Erbas T., Park TS, Nolan R., Pittenger GL Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24:1476-1485.
39. Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis, and thrombosis. Thromb Haemost. 2008;99:995-1000.
40. Natarajan A., Zaman AG, Marshall SM Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab Vasc Dis Res. 2008;5:138-144.
41. Nomura S., Kanazawa S., Fukuhara S. Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with type 2 diabetes mellitus. J Diabetes Complications. 2003;17:153-159.
42. Chung I., Lip GY Virchow's triad revisited: blood constituents. Pathophysiol Haemost Thromb. 2003;33:449-454.
43. Ryan M., McInerney D., Owens D., Collins P., Johnson A., Tomkin GH Diabetes and the Mediterranean diet: a beneficial effect of oleic acid on insulin sensitivity, adipocyte glucose transport and endothelium-dependent vasoreactivity. QJM. 2000;93:85-91.
44. Goodnight SH, Harris WS, Connor WE, Illingworth DR Polyunsaturated fatty acids, hyperlipidemia, and thrombosis. Arteriosclerosis. 1982;2:87-113.
45. Burdge GC, Calder PC Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod Nutr Dev. 2005;45:581-597.
46. Colussi G., Catena C., Baroselli S.,et al.Omega-3 fatty acids: from biochemistry to their clinical use in the prevention of cardiovascular disease. Recent Patents Cardiovasc Drug Discov. 2007;2:13-21.
47. Din JN, Newby DE, Flapan AD Omega 3 fatty acids and cardiovascular disease-fishing for a natural treatment. BMJ. 2004;328:30-35.
48. Jenkins DJ, Josse AR Fish oil and omega-3 fatty acids. CMAJ. 2008; 178:150.
49. Surette ME The science behind dietary omega-3 fatty acids. CMAJ. 2008;178:177-180.
50. Harris WS, Kris-Etherton PM, Harris KA Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults. Curr Atheroscler Rep. 2008;10:503-509.
51. Ruxton C. Health benefits of omega-3 fatty acids. Nurs Stand. 2004;18:38-42.
52. Valentine RC, Valentine DL Omega-3 fatty acids in cellular membranes: a unified concept. Prog Lipid Res. 2004;43:383-402.
53. Kris-Etherton PM, Harris WS, Appel LJ Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2003;23:e20-30.
54. Mozaffarian D., Rimm EB Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006;296: 1885-1899.
55. Annuzzi G., Rivellese A., Capaldo B.,et al.A controlled study on the effects of n-3 fatty acids on lipid and glucose metabolism in non-insulin-dependent diabetic patients. Atherosclerosis. 1991;87: 65-73.
56. Barcelli U., Glas-Greenwalt P., Pollak VE Enhancing effect of dietary supplementation with omega-3 fatty acids on plasma fibrinolysis in normal subjects. Thromb Res. 1985;39:307-312.
57. Grundt H., Nilsen DW, Hetland O., Mansoor MA Clinical outcome and atherothrombogenic risk profile after prolonged washout following long-term treatment with high doses of n-3 PUFAs in patients with an acute myocardial infarction. Clin Nutr. 2004;23:491-500.
58. Mori TA, Vandongen R., Beilin LJ, Burke V., Morris J., Ritchie J. Effects of varying dietary fat, fish, and fish oils on blood lipids in a randomized controlled trial in men at risk of heart disease. Am J Clin Nutr. 1994;59:1060-1068.
59. Mori TA, Vandongen R., Masarei JR Fish oil-induced changes in apolipoproteins in IDDM subjects. Diabetes Care. 1990;13:725-732.
60. Mozaffarian D. Fish oil and prevention of atrial fibrillation. J Am Coll Cardiol. 2007;50:1513-1514.
61. Mozaffarian D., Prineas RJ, Stein PK, Siscovick DS Dietary fish and n-3 fatty acid intake and cardiac electrocardiographic parameters in humans. J Am Coll Cardiol. 2006;48:478-484.
62. Mozaffarian D., Psaty BM, Rimm EB,et al.Fish intake and risk of incident atrial fibrillation. Circulation. 2004;110:368-373.
63. Rivellese AA, Maffettone A., Iovine C.,et al.Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. Diabetes Care. 1996;19:1207-1213.
64. Streppel MT, Ocke MC, Boshuizen HC, Kok FJ, Kromhout D. Long-term fish consumption and n-3 fatty acid intake in relation to (sudden) coronary heart disease death: the Zutphen study. Eur Heart J. 2008;29:2024-2030.
65. Tavazzi L., Maggioni AP, Marchioli R.,et al.Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223-1230.
66. Yokoyama M., Origasa H., Matsuzaki M.,et al.Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090-1098.
67. Cao J., Schwichtenberg KA, Hanson NQ, Tsai MY Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clin Chem. 2006;52:2265-2272.
68. De Caterina R., Madonna R., Zucchi R., La Rovere MT Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside. Am Heart J. 2003;146:420-430.
69. Zhang J., Sasaki S., Amano K., Kesteloot H. Fish consumption and mortality from all causes, ischemic heart disease, and stroke: an ecological study. Prev Med. 1999; 28:520-529.
70. Ascherio A., Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med. 1995;332: 977-982.
71. Connor WE, Prince MJ, Ullmann D.,et al.The hypotriglyceridemic effect of fish oil in adult-onset diabetes without adverse glucose control. Ann N Y Acad Sci. 1993;683:337-340.
72. Luo J., Rizkalla SW, Vidal H.,et al.Moderate intake of n-3 fatty acids for 2 months has no detrimental effect on glucose metabolism and could ameliorate the lipid profile in type 2 diabetic men. Results of a controlled study. Diabetes Care. 1998;21:717-724.
73. Mori TA, Burke V., Puddey IB,et al.Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr. 2000;71:1085-1094.
74. Sirtori CR, Paoletti R., Mancini M.,et al.n-3 fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance. Italian Fish Oil Multicenter Study. Am J Clin Nutr. 1997;65:1874-1881.
75. Vanschoonbeek K., Feijge MA, Paquay M.,et al.Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation. Arterioscler Thromb Vasc Biol. 2004;24:1734-1740.
76. Mostad IL, Bjerve KS, Lydersen S., Grill V. Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes. Eur J Clin Nutr. 2008;62:419-429.
77. Din JN, Harding SA, Valerio CJ,et al.Dietary intervention with oil rich fish reduces platelet-monocyte aggregation in man. Atherosclerosis. 2008;197:290-296.
78. Calder PC n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83:1505S-1519S.
79. Rodriguez BL, Sharp DS, Abbott RD,et al.Fish intake may limit the increase in risk of coronary heart disease morbidity and mortality among heavy smokers. The Honolulu Heart Program. Circulation. 1996;94:952-956.
80. Kabir M., Skurnik G., Naour N.,et al.Treatment for 2 months with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr. 2007;86:1670-1679.
81. Mozaffarian D., Longstreth WT, Lemaitre RN,et al.Fish consumption and stroke risk in elderly individuals: the cardiovascular health study. Arch Intern Med. 2005;165:200-206.
82. Kris-Etherton PM, Harris WS, Appel LJ Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23: 151-152.
83. McClaskey EM, Michalets EL Subdural hematoma after a fall in an elderly patient taking high-dose omega-3 fatty acids with warfarin and aspirin: case report and review of the literature. Pharmacotherapy. 2007;27:152-160.
84. Harris WS Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol. 2007;99:44C-46C.
85. Riediger ND, Othman RA, Suh M., Moghadasian MH A systemic review of the roles of n-3 fatty acids in health and disease. J Am Diet Assoc. 2009;109:668-679.
86. Ginsberg GL, Toal BF Quantitative approach for incorporating methylmercury risks and omega-3 fatty acid benefits in developing species-specific fish consumption advice. Environ Health Perspect. 2009;117:267-275.
87. Rice DC Overview of modifiers of methylmercury neurotoxicity: chemicals, nutrients, and the social environment. Neurotoxicology. 2008;29:761-766.
88. Myint PK, Welch AA, Bingham SA,et al.Habitual fish consumption and risk of incident stroke: the European Prospective Investigation into Cancer (EPIC)-Norfolk prospective population study. Public Health Nutr. 2006;9:882-888.
89. Bays HE Safety considerations with omega-3 fatty acid therapy. Am J Cardiol. 2007;99:35C-43C.